20 October 2026
Physiomics plc
("Physiomics" or the "Company")
Contract Award
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract award valued at £102,000 for model-informed drug development ("MIDD") modelling, incorporating pharmacokinetic/pharmacodynamic ("PK/PD") modelling.
Ian Bagnall, Finance Director of Physiomics, said:
"This contract is yet another example of our team's ability to win new business, which is very pleasing to see. This contract brings the total value of contract awards announced since May 2026 to more than £970,000 , which compares with revenue of £941,222 reported in our recently released Annual Report for the year ended 30 June 2026 ("FY26"). Together with the full year impact of the cost reductions, our investment in our IT systems and strong pipeline of potential projects, the Directors look forward to further progress being made during the current financial year.
"I would also like to comment on certain investor speculation that the Company accepts loss making contracts. No contracts are accepted which would knowingly result in a loss on the work programme. As set out in our Annual Report, increased use of external contractors added to costs in FY26, particularly in the first half, and this has since been significantly reduced. The focus of the new team is very much upon growing the revenue but ensuring financial rigour and tight cost controls."
ENDS
For more information about Physiomics and its services, please visit www.physiomics.co.uk.
Enquiries:
|
Physiomics plc Mike Whitlow |
Email: info@physiomics.co.uk |
|
Strand Hanson Ltd (NOMAD and Broker) James Dance & James Bellman |
Tel: +44 (0) 20 7409 3494 |
About Physiomics
Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.